Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1747-1754

  Van Acker, Saskia A B E ^a   Boven, Epie ^a   Kuiper, Karin ^a   Van Den Berg, Dirk Jan ^a   Grimbergen, Joop A ^a   Kramer, Klaas ^a   Bast, Aalt ^a   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; DOXORUBICIN; KAEMPFEROL; MONOXERUTIN; QUERCETIN; RAZOXANE; RUTOSIDE; TAXIFOLIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; DOSE RESPONSE; ELECTROCARDIOGRAM; HEART PROTECTION; HEART TUMOR; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BREAST NEOPLASMS; CARDIOMYOPATHIES; CATECHIN; CHELATION THERAPY; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; FLAVONOIDS; FLAVONOLS; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; HYDROXYETHYLRUTOSIDE; IRON; IRON CHELATING AGENTS; KAEMPFEROLS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; QUERCETIN; RAZOXANE; RUTIN; TELEMETRY; TUMOR CELLS, CULTURED; WEIGHT LOSS;

EID: 0030801562     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., and Young, R. C. Adriamycin. The role of lipid peroxidation in cardiac toxicity and tumor response. Science (Washington DC), 197: 165-167, 1977.
2. van Acker, S. A. B. E., Kramer, K., van den Berg, D-J., Grimbergen, J. A., van der Vijgh, W. J. F., and Bast, A. Monohydroxyethylrutoside as protector against doxorubicin-induced cardiotoxicity. Br. J. Pharmacol., 115: 1260-1264, 1995.
3. Koning, J., Palmer, P., Franks, C. R., Mulder, D. E., Speyer, J. L., Green, M. D., and Hellmann, K. Cardioxane: ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat. Rev., 18: 1-19, 1991.
4. van Acker, S. A. B. E., Towart, R., Hüsken, B. C. P., de Jong, J., van der Vijgh, W. J. F., and Bast, A. The protective effect of Venoruton and its main constituents on acute doxorubicin-induced cardiotoxicity. Phlebology, Suppl. 1: 31-32, 1993.
5. Haenen, G. R. M. M., Jansen, F. P., and Bast, A. The antioxidant properties of five O-(β-Hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology, Suppl. 1: 10-17, 1993.
6. van Acker, S. A. B. E., Voest, E. E., Beems, D. B., Madhuizen, H. T., De Jong, J., Bast, A., and van der Vijgh, W. J. F. Cardioprotective properties of O-(β-hydroxyethyl)-rutosides in doxorubicin-pretreated Balb/c mice. Cancer Res., 53: 4603-4607, 1993.
7. Kramer, K., van Acker, S. A. B. E., Voss, H. P., Grimbergen, J. A., van der Vijgh, W. J. F., and Bast, A. Use of telemetry to record electrocardiogram and heart rate in freely moving mice. J. Pharmacol. Toxicol. Methods, 30: 209-215, 1993.
8. Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., S. R. T., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., Westin, E. H., Wong-Staal, F., Gallo, R. C., and Aaronson, S. A. Cellular genes analogous to retroviral one genes are transcribed in human tumour cells. Nature (Lond.), 295: 116-119, 1982.
9. Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang-Peng, J., Rogan, A. M., Green, W. R., and Ozols, R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res., 43: 5379-5389, 1983.
10. Soule, H. D., Vazquez, J., Long, A., Albert, S., and Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. (Bethesda), 51: 1409-1416, 1973.
11. Keepers, Y. P., Pizao, P. E., Peters, G. J., Van Ark-Otte, J., Winograd, B., and Pinedo, H. M. Comparison of the sulforhodamin B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer, 27: 897-900, 1991.
12. Boven, E., Winograd, B., Berger, D. P., Dumont, M. P., Braakhuis, B. J. M., Fodstad, Ø., Langdon, S., and Fiebig, H. H. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res., 52: 5940-5947, 1992.
13. Boven, E., Hendriks, H. R., Erkelens, C. A. M., and Pinedo, H. M. The anti-tumour effects of the prodrugs N-L[D]-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br. J. Cancer, 66: 1044-1047, 1992.
14. van Acker, S. A. B. E., Kramer, K., Grimbergen, J. A., van der Vijgh, W. J. F., and Bast, A. Doxorubicin-induced chronic cardiotoxicity measured in freely moving mice. In: W. J. Zeller (ed.). Contributions to Oncology, Vol. 48, pp. 30-39. Basel: S. Karger AG, 1995.
15. Postan, M., Bailey, J. J., Dvorak, J. A., McDaniel, J. P., and Pottala, E. W. Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection. Am. J. Trop. Med. Hyg., 37: 541-549, 1987.
16. Monath, T. P., Kemp, G. E., Cropp, C. B., and Chandler, F. W. Necrotizing myocarditis in mice infected with Western equine encephalitis virus: clinical, electrocardiographic, and histopathologic correlations. J. Infect. Dis., 138: 59-66, 1978.
17. Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Cordon, B., Locker, G., Doroshow, J., and Epstein, S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol., 10: 53-55, 1991.
18. McGinness, J. E., Grossie, B. J., Proctor, P. H., Benjamin, R. S., Gulati, O. P., and Hokanson, J. A. Effect of dose schedule of vitamin E and hydroxyethyl-ruticide on intestinal toxicity induced by adriamycin. Physiol. Chem. Phys. Med. NMR, 18: 17-24, 1986.
19. Herman, E. H., and Ferrans, V. J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest., 49: 69-77, 1983.
20. Pritsos, C. A., Sokoloff, M., and Gustafson, D. L. PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem. Pharmacol., 44: 839-841, 1992.
21. Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jaquotte, A., Wernz, J., Feit, F., Slater, W., Blum, R., and Muggia, F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319: 745-752, 1988.
22. Rekka, E., and Kourounakis, P. N. Effect of hydroxyethyl rutosides and related compounds on lipid peroxidation and free radical scavenging activity. Some structural aspects. J. Pharm. Pharmacol., 43: 486-491, 1991.
23. Parachini, L., Jotti, A., Bottiroli, G., Prosperi, E., Supino, R., and Piccinini, F. The spin trap α-phenyl-tert-butyl nitrone protects against myelotoxicity and cardiotoxicity of adriamycin while preserving the cytotoxic activity. Anticancer Res., 13: 1607-1612, 1993.
24. Seyedin, A., Sheykhzade, M., and Hermansen, K. The electrocardiogram from mice as a model to study anthracycline cardiotoxicity. Br. J. Pharmacol., 111: 275P, 1994.
25. van Acker, S. A. B. E., Kramer, K., Voest, E. E., Grimbergen, J. A., Zhang, J., van der Vijgh, W. J. F., and Bast, A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A model to test potential protectors. Cancer Chemother. Pharmacol., 38: 95-101, 1996.
26. Hackett, A. M., and Griffiths, L. A. The disposition and metabolism of 3′,4′,7-tri-O-(β-hydroxyethyl)rutoside and 7-mono-O-(β-hydroxyethyl)rutoside in the mouse. Xenobiotica, 7: 641-651, 1977.
27. Bull, J. M. C., Strebel, F. R., Sunderland, B. A., Bulger, R. E., Edwards, M., Siddik, Z. H., and Newman, R. A. O-(β-hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(H)/hyperthermia treatment. Cancer Res., 48: 2239-2244, 1988.
28. Liu, B., Anderson, D., Ferry, D. R., Seymour, L. W., De Takats, P. G., and Kerr, D. J. Determination of quercetin in human plasma using reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl, 666: 149-155, 1995.